Lab
Cirrus DX, INC.
Cirrus DX, INC. was paid $907K by Medicaid between Jan 2018 and Dec 2024, across 25 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 32% of everything it billed.
33Billing provider infoCIRRUS DX, INC.
ROCKVILLE, MD 20850
ROCKVILLE, MD 20850
33aNPI1861913576assigned 07/03/2017
33bProvider typeClinical Medical Laboratory
28Total paid$907K
24GClaims70,056
24DCodes billed25
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Maryland
Rank by total paid#38 of 93
Median peer was paid$430K
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,353 | $234K | |
| 2019 | 1,518 | $69K | |
| 2020 | 4,676 | $103K | |
| 2021 | 10,243 | $82K | |
| 2022 | 25,661 | $163K | |
| 2023 | 9,476 | $62K | |
| 2024incomplete | 14,129 | $194K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 32% | 12,987 | 3,499 | $290K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 20% | 4,535 | 3,805 | $179K |
| 87799 | 8.2% | 2,566 | 2,287 | $74K | |
| 87900 | 8.0% | 3,200 | 2,853 | $72K | |
| 87481 | 4.6% | 4,065 | 3,704 | $42K | |
| 87500 | 3.8% | 4,888 | 4,389 | $34K | |
| 87653 | 3.6% | 4,131 | 3,760 | $33K | |
| 87641 | 3.6% | 4,103 | 3,739 | $33K | |
| 87652 | 3.3% | 3,366 | 3,007 | $30K | |
| 87640 | 3.2% | 3,769 | 3,409 | $29K | |
| 87186 | 2.6% | 3,516 | 3,190 | $24K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 8,574 | 1,738 | $21K |
13 more codes
| 87482 | 1.2% | 2,169 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 1,415 | $10K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 472 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 472 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 469 | $5K |
| 87563 | <1% | 3,157 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 697 | $3K |
| 87800 | <1% | 655 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 25 | $356.67 |
| 87590 | <1% | 122 | $216.55 | |
| 87490 | <1% | 122 | $204.33 | |
| 81005 | <1% | 458 | $134.38 | |
| 87660 | <1% | 123 | $16.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOFTIN, CAROL (BILLING ADMINISTRATOR)